Palsonify
Palsonify ingredients
| Active ingredient | Strength |
|---|---|
| Paltusotine Hydrochloride | 20 mg/1, 30 mg/1 |
What Palsonify is used for
The FDA lists the approved uses on the official label (below). In the EU, paltusotine is approved as Palsonify for:
Palsonify is indicated for the medical treatment of adult patients with acromegaly.
EU wording from the European Medicines Agency; US approved uses can differ.
Key facts
- Brand
- Palsonify
- Generic name
- Paltusotine
- Made by
- Crinetics Pharmaceuticals, Inc.
- Forms
- Tablet, Film Coated
- Given
- Oral
- FDA approval
- New drug application (NDA) NDA219070
- On the US market since
- 2025
Official information
- Palsonify prescribing information (FDA label) on DailyMed
- MedlinePlus drug information (search for Paltusotine)
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Palsonify?
Palsonify (Paltusotine) is a specialist medicine made by Crinetics Pharmaceuticals, Inc., approved by the US FDA.
What are the ingredients of Palsonify?
Palsonify contains Paltusotine Hydrochloride (20 mg/1, 30 mg/1).
Is Palsonify approved in Europe?
The same active substance is approved in the EU as Palsonify.
From the FDA National Drug Code directory (open.fda.gov, public domain) and the European Medicines Agency medicines list. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, USA